Aclaris Therapeutics, Inc. (ACRS)

NMS – Real Time Price. Currency in USD

4.88

-0.07 (-1.41%)

At close: May 12, 2026, 4:00 PM EDT

4.83

-0.05 (-0.92%)

After-hours: May 12, 2026, 7:58 PM EDT

08.05.2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

WAYNE, Pa., May 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday May 14, 2026, at 9:35 AM PT, Aclaris' President and Chief Operating Officer Dr. Hugh Davis will provide a corporate presentation during the 2026 Bank of America Healthcare Conference in Las Vegas, NV. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com.

07.05.2026

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.

07.05.2026

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Full Top Line Results from Phase 1a SAD/MAD Trial of ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Unique Dual Mechanism of ATI-2138 Supports Planned Phase 2b Clinical Trial in Lichen Planus - - Strong Cash Runway Expected to Enable Development of Pipeline Through 2028 - WAYNE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2026 and provided a corporate and clinical update.

28.04.2026

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

28.04.2026

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

- Positive Full Results from Phase 1a Trial of Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 Exceed Aclaris' Target Profile, Validating Potential Best-in-Class Potency Advantage and Opportunity for Extended Dosing - - Estimated Half-Life of Approximately 45 Days; Unlocks Opportunity for up to Three-Month Dosing Interval - - Complete and Sustained Inhibition of TSLP-Induced and IL-4 Induced CCL17 (TARC) Provides Potential to Raise Efficacy Ceiling in Th2-Driven Diseases - - Enrollment and Dosing Ongoing in Phase 1b Trials in Asthma and Atopic Dermatitis (AD) with Top Line Results Expected in the Second Half of 2026 - - Lichen Planus Selected as Lead Indication for ATI-2138; Potential to be First Mechanistically Complete Therapeutic Candidate Designed to Address Root Inflammation and Symptoms - - Management to Host a Conference Call to Discuss Update Today at 8:30 AM EST - WAYNE, Pa., April 28, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today provided a clinical update on its biologic and oral inhibitor compounds including positive full top line results from the first-in-human Phase 1a single (SAD) and multiple ascending dose (MAD) trial of its anti-TSLP/IL-4Rα bispecific antibody ATI-052 and the selection of lichen planus (LP) as the lead indication for its selective ITK/JAK3 inhibitor ATI-2138.

27.04.2026

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026. Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates.

08.04.2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

WAYNE, Pa., April 08, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Tuesday, April 14, 2026, at 12:00 PM EDT, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference.

Videos

No Data

There is no data to display

Press releases

08.05.2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

07.05.2026

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

28.04.2026

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

27.04.2026

Aclaris Therapeutics, Inc. (ACRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Videos

No Data

Press releases

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Videos

No Data

Press releases

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Search stocks

Aclaris Therapeutics, Inc. (ACRS)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Aclaris Therapeutics, Inc. (ACRS)

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Videos

No Data

Press releases

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics, Inc. (ACRS) Discusses Clinical Program Update and Progress of Lead Bispecific Antibody Candidates Transcript

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026

Aclaris Therapeutics to Participate in the H.C. Wainwright 4th Annual Inflammatory Skin Disease Virtual Conference

Videos

No Data

Press releases

Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference

Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update

Aclaris Therapeutics Announces Positive Full Top Line First-in-Human Results from Phase 1a Healthy Volunteer Clinical Trial of ATI-052, a Novel Potential First-in-Class Anti-TSLP/IL-4Rα Bispecific Antibody, and Announces Lichen Planus as Lead Indication for ATI-2138, an Oral ITK/JAK3 Inhibitor

Aclaris Therapeutics to Provide Clinical Update on Key Biologic and Oral Inhibitor Programs on April 28, 2026